223 related articles for article (PubMed ID: 22080198)
1. [Cannabinoids for symptomatic therapy of multiple sclerosis].
Husseini L; Leussink VI; Warnke C; Hartung HP; Kieseier BC
Nervenarzt; 2012 Jun; 83(6):695-704. PubMed ID: 22080198
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.
Leussink VI; Husseini L; Warnke C; Broussalis E; Hartung HP; Kieseier BC
Ther Adv Neurol Disord; 2012 Sep; 5(5):255-66. PubMed ID: 22973422
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Oreja-Guevara C
Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
[TBL] [Abstract][Full Text] [Related]
4. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?].
Trebst C; Stangel M
Fortschr Neurol Psychiatr; 2005 Aug; 73(8):463-9. PubMed ID: 16052440
[TBL] [Abstract][Full Text] [Related]
5. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
Centonze D; Mori F; Koch G; Buttari F; Codecà C; Rossi S; Cencioni MT; Bari M; Fiore S; Bernardi G; Battistini L; Maccarrone M
Neurol Sci; 2009 Dec; 30(6):531-4. PubMed ID: 19768368
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
8. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
Collin C; Davies P; Mutiboko IK; Ratcliffe S;
Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
[TBL] [Abstract][Full Text] [Related]
10. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Bazinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
[TBL] [Abstract][Full Text] [Related]
11. Towards cannabis and cannabinoid treatment of multiple sclerosis.
Croxford JL; Miller SD
Drugs Today (Barc); 2004 Aug; 40(8):663-76. PubMed ID: 15510238
[TBL] [Abstract][Full Text] [Related]
12. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Flachenecker P
Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
[TBL] [Abstract][Full Text] [Related]
13. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Basinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
[TBL] [Abstract][Full Text] [Related]
14. Do cannabinoids reduce multiple sclerosis-related spasticity?
Thaera GM; Wellik KE; Carter JL; Demaerschalk BM; Wingerchuk DM
Neurologist; 2009 Nov; 15(6):369-71. PubMed ID: 19901724
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
Meuth SG; Vila C; Dechant KL
Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Russo EB
Neurology; 2003 Feb; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
[No Abstract] [Full Text] [Related]
17. The endocannabinoid system and multiple sclerosis.
Baker D; Pryce G
Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
[TBL] [Abstract][Full Text] [Related]
18. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
19. [Cannabinoids in multiple sclerosis. Opportunity or hazard?].
Neuhaus O; Kieseier BC; Klimke A; Gaebel W; Hohlfeld R; Hartung HP
Nervenarzt; 2004 Oct; 75(10):1022-6. PubMed ID: 15156287
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Zajicek J; Fox P; Sanders H; Wright D; Vickery J; Nunn A; Thompson A;
Lancet; 2003 Nov; 362(9395):1517-26. PubMed ID: 14615106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
